Shenzhen Neptunus Bioengineering Co., Ltd. (SHE:000078)

China flag China · Delayed Price · Currency is CNY
3.510
+0.060 (1.74%)
Feb 24, 2026, 3:04 PM CST
Market Cap9.08B +39.7%
Revenue (ttm)27.28B -15.6%
Net Income-1.21B
EPS-0.46
Shares Out2.63B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume66,081,157
Average Volume172,946,062
Open3.470
Previous Close3.450
Day's Range3.470 - 3.530
52-Week Range2.080 - 5.700
Beta0.32
RSI41.01
Earnings DateApr 29, 2026

About SHE:000078

Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and other medical research and development work. It also distributes drugs, medical devices, and other medical supplies; and offers value-added services for ho... [Read more]

Sector Healthcare
Founded 1992
Employees 8,264
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 000078
Full Company Profile

Financial Performance

In 2024, SHE:000078's revenue was 30.32 billion, a decrease of -16.75% compared to the previous year's 36.42 billion. Losses were -1.19 billion, -29.38% less than in 2023.

Financial Statements